The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Targeting the cancer epigenome for therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
DNA methylation age of human tissues and cell types
Horvath, S. (2013) · Genome Biology · doi:10.1186/gb-2013-14-10-r115 · Cited by 7,075
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Integrative analysis of 111 reference human epigenomes
Roadmap Epigenomics Consortium, Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., Heravi-Moussavi, A., Kheradpour, P., Zhang, Z., Wang, J., et al. (2015) · Nature · doi:10.1038/nature14248 · Cited by 6,368
Jaenisch, R., & Bird, A. (2003) · Nature Genetics · doi:10.1038/ng1089 · Cited by 6,325
Functions of DNA methylation: islands, start sites, gene bodies and beyond
Jones, P. A. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3230 · Cited by 6,061
Self-citationDruker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Self-citationSelective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J. R., Cole, P. A., Casero, R. A., & Shi, Y. (2004) · Cell · doi:10.1016/j.cell.2004.12.012 · Cited by 4,051
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
Self-citationCancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Genomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151
Self-citationSelective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
Self-citationBET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.011 · Cited by 2,022
Self-citationIDH mutation impairs histone demethylation and results in a block to cell differentiation
Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012) · Nature · doi:10.1038/nature10860 · Cited by 1,985
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., et al. (2012) · Nature · doi:10.1038/nature10866 · Cited by 1,974
Cameron, E. E., Bachman, K. E., Myöhänen, S., Herman, J. G., & Baylin, S. B. (1999) · Nature Genetics · doi:10.1038/5047 · Cited by 1,857
Self-citationCellular differentiation, cytidine analogs and DNA methylation
Jones, P. A., & Taylor, S. M. (1980) · Cell · doi:10.1016/0092-8674(80)90237-8 · Cited by 1,831
Self-citationMethylation-Induced Repression— Belts, Braces, and Chromatin
Bird, A. P., & Wolffe, A. P. (1999) · Cell · doi:10.1016/s0092-8674(00)81532-9 · Cited by 1,827
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
Roulois, D., Loo Yau, H., Singhania, R., Wang, Y., Danesh, A., Shen, S. Y., Han, H., Liang, G., Jones, P. A., Pugh, T. J., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.056 · Cited by 1,527
Self-citationMorin, R. D., Johnson, N. A., Severson, T. M., Mungall, A. J., An, J., Goya, R., Paul, J. E., Boyle, M., Woolcock, B. W., Kuchenbauer, F., et al. (2010) · Nature Genetics · doi:10.1038/ng.518 · Cited by 1,521
Saito, Y., Liang, G., Egger, G., Friedman, J. M., Chuang, J. C., Coetzee, G. A., & Jones, P. A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.020 · Cited by 1,335
Self-citationInsulator dysfunction and oncogene activation in IDH mutant gliomas
Flavahan, W. A., Drier, Y., Liau, B. B., Gillespie, S. M., Venteicher, A. S., Stemmer-Rachamimov, A. O., Suvà, M. L., & Bernstein, B. E. (2016) · Nature · doi:10.1038/nature16490 · Cited by 1,288
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201
Gene Body Methylation Can Alter Gene Expression and Is a Therapeutic Target in Cancer
Yang, X., Han, H., De Carvalho, D. D., Lay, F. D., Jones, P. A., & Liang, G. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.028 · Cited by 1,199
Self-citationMethylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon
Issa, J.-P. J., Ottaviano, Y. L., Celano, P., Hamilton, S. R., Davidson, N. E., & Baylin, S. B. (1994) · Nature Genetics · doi:10.1038/ng0894-536 · Cited by 1,191
Self-citationCancer Genetics and Epigenetics: Two Sides of the Same Coin?
You, J. S., & Jones, P. A. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.008 · Cited by 1,167
Self-citationAn inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, J., Clark, O., Oldrini, B., Komisopoulou, E., et al. (2013) · Science · doi:10.1126/science.1236062 · Cited by 1,153
Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a
Janzen, V., Forkert, R., Fleming, H. E., Saito, Y., Waring, M. T., Dombkowski, D. M., Cheng, T., DePinho, R. A., Sharpless, N. E., & Scadden, D. T. (2006) · Nature · doi:10.1038/nature05159 · Cited by 1,106
Histone core modifications regulating nucleosome structure and dynamics
Tessarz, P., & Kouzarides, T. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3890 · Cited by 1,018
Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Majer, C. R., Sneeringer, C. J., Song, J., Johnston, L. D., Scott, M. P., Smith, J. J., Xiao, Y., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.009 · Cited by 923
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914
Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells
Blaschke, K., Ebata, K. T., Karimi, M. M., Zepeda-Martínez, J. A., Goyal, P., Mahapatra, S., Tam, A., Laird, D. J., Hirst, M., Rao, A., et al. (2013) · Nature · doi:10.1038/nature12362 · Cited by 865
Suzuki, H., Gabrielson, E., Chen, W., Anbazhagan, R., van Engeland, M., Weijenberg, M. P., Herman, J. G., & Baylin, S. B. (2002) · Nature Genetics · doi:10.1038/ng892 · Cited by 857
Self-citationKadoch, C., & Crabtree, G. R. (2015) · Science Advances · doi:10.1126/sciadv.1500447 · Cited by 828
Bender, S., Tang, Y., Lindroth, A. M., Hovestadt, V., Jones, D. T. W., Kool, M., Zapatka, M., Northcott, P. A., Sturm, D., Wang, W., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.006 · Cited by 818
Issa, J.-P. J., Garcia-Manero, G., Giles, F. J., Mannari, R., Thomas, D., Faderl, S., Bayar, E., Lyons, J., Rosenfeld, C. S., Cortes, J., et al. (2004) · Blood · doi:10.1182/blood-2003-03-0687 · Cited by 809
Self-citationSan-Miguel, J. F., Hungria, V. T. M., Yoon, S.-S., Beksac, M., Dimopoulos, M. A., Elghandour, A., Jedrzejczak, W. W., Günther, A., Nakorn, T. N., Siritanaratkul, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70440-1 · Cited by 791
Chemical phylogenetics of histone deacetylases
Bradner, J. E., West, N., Grachan, M. L., Greenberg, E. F., Haggarty, S. J., Warnow, T., & Mazitschek, R. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.313 · Cited by 720
Tuveson, D. A., Willis, N. A., Jacks, T., Griffin, J. D., Singer, S., Fletcher, C. D., Fletcher, J. A., & Demetri, G. D. (2001) · Oncogene · doi:10.1038/sj.onc.1204704 · Cited by 695
Mechanisms of Immune Evasion by Tumors
Drake, C. G., Jaffee, E., & Pardoll, D. M. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90002-9 · Cited by 688
Juergens, R. A., Wrangle, J., Vendetti, F. P., Murphy, S. C., Zhao, M., Coleman, B., Sebree, R., Rodgers, K., Hooker, C. M., Franco, N., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0214 · Cited by 686
Self-citationKantarjian, H., Oki, Y., Garcia-Manero, G., Huang, X., O'Brien, S., Cortes, J., Faderl, S., Bueso-Ramos, C., Ravandi, F., Estrov, Z., et al. (2007) · Blood · doi:10.1182/blood-2006-05-021162 · Cited by 685
Self-citationBerman, B. P., Weisenberger, D. J., Aman, J. F., Hinoue, T., Ramjan, Z., Liu, Y., Noushmehr, H., Lange, C. P. E., van Dijk, C. M., Tollenaar, R. A. E. M., et al. (2012) · Nature Genetics · doi:10.1038/ng.969 · Cited by 660
Tsai, H.-C., Li, H., Van Neste, L., Cai, Y., Robert, C., Rassool, F. V., Shin, J. J., Harbom, K. M., Beaty, R., Pappou, E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.029 · Cited by 650
Self-citation5-Methylcytosine as an Endogenous Mutagen in the Human LDL Receptor and p53 Genes
Rideout, W. M., Coetzee, G. A., Olumi, A. F., & Jones, P. A. (1990) · Science · doi:10.1126/science.1697983 · Cited by 640
Self-citationChanges in DNA Methylation Patterns in Subjects Exposed to Low-Dose Benzene
Bollati, V., Baccarelli, A., Hou, L., Bonzini, M., Fustinoni, S., Cavallo, D., Byun, H.-M., Jiang, J., Marinelli, B., Pesatori, A. C., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2995 · Cited by 612
Epigenomic alterations define lethal CIMP-positive ependymomas of infancy
Mack, S. C., Witt, H., Piro, R. M., Gu, L., Zuyderduyn, S., Stütz, A. M., Wang, X., Gallo, M., Garzia, L., Zayne, K., et al. (2014) · Nature · doi:10.1038/nature13108 · Cited by 607
Johann, P. D., Erkek, S., Zapatka, M., Kerl, K., Buchhalter, I., Hovestadt, V., Jones, D. T. W., Sturm, D., Hermann, C., Segura Wang, M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.001 · Cited by 571
Wijermans, P., Lübbert, M., Verhoef, G., Bosly, A., Ravoet, C., Andre, M., & Ferrant, A. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.956 · Cited by 567
O'Hagan, H. M., Wang, W., Sen, S., DeStefano Shields, C., Lee, S. S., Zhang, Y. W., Clements, E. G., Cai, Y., Van Neste, L., Easwaran, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.012 · Cited by 563
Self-citationTET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
Bejar, R., Lord, A., Stevenson, K., Bar-Natan, M., Pérez-Ladaga, A., Zaneveld, J., Wang, H., Caughey, B., Stojanov, P., Getz, G., et al. (2014) · Blood · doi:10.1182/blood-2014-06-582809 · Cited by 562
Chou, D. M., Adamson, B., Dephoure, N. E., Tan, X., Nottke, A. C., Hurov, K. E., Gygi, S. P., Colaiácovo, M. P., & Elledge, S. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012946107 · Cited by 529
Daskalakis, M., Nguyen, T. T., Nguyen, C., Guldberg, P., Köhler, G., Wijermans, P., Jones, P. A., & Lübbert, M. (2002) · Blood · doi:10.1182/blood.v100.8.2957 · Cited by 514
Self-citationA DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC
Mohammad, H. P., Smitheman, K. N., Kamat, C. D., Soong, D., Federowicz, K. E., Van Aller, G. S., Schneck, J. L., Carson, J. D., Liu, Y., Butticello, M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.06.002 · Cited by 504
Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
Prébet, T., Gore, S. D., Esterni, B., Gardin, C., Itzykson, R., Thepot, S., Dreyfus, F., Rauzy, O. B., Recher, C., Adès, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.8135 · Cited by 475
Itzykson, R., Kosmider, O., Cluzeau, T., Mansat-De Mas, V, Dreyfus, F., Beyne-Rauzy, O., Quesnel, B., Vey, N., Gelsi-Boyer, V, Raynaud, S., et al. (2011) · Leukemia · doi:10.1038/leu.2011.71 · Cited by 471
Russler-Germain, D. A., Spencer, D. H., Young, M. A., Lamprecht, T. L., Miller, C. A., Fulton, R., Meyer, M. R., Erdmann-Gilmore, P., Townsend, R. R., Wilson, R. K., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.010 · Cited by 452
Issa, J.-P. J., & Kantarjian, H. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2783 · Cited by 446
Self-citationExtreme vulnerability of IDH1 mutant cancers to NAD+ depletion
Tateishi, K., Wakimoto, H., Iafrate, A. J., Tanaka, S., Loebel, F., Lelic, N., Wiederschain, D., Bedel, O., Deng, G., Zhang, B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.11.006 · Cited by 433
A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation
Kaufman, C. K., Mosimann, C., Fan, Z. P., Yang, S., Thomas, A. J., Ablain, J., Tan, J. L., Fogley, R. D., van Rooijen, E., Hagedorn, E. J., et al. (2016) · Science · doi:10.1126/science.aad2197 · Cited by 398
Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape
Lu, C., Jain, S. U., Hoelper, D., Bechet, D., Molden, R. C., Ran, L., Murphy, D., Venneti, S., Hameed, M., Pawel, B. R., et al. (2016) · Science · doi:10.1126/science.aac7272 · Cited by 392
Epigenetic Resensitization to Platinum in Ovarian Cancer
Matei, D., Fang, F., Shen, C., Schilder, J., Arnold, A., Zeng, Y., Berry, W. A., Huang, T., & Nephew, K. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3909 · Cited by 390
O'Hagan, H. M., Mohammad, H. P., & Baylin, S. B. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000155 · Cited by 386
Self-citationAlterations of immune response of non-small cell lung cancer with Azacytidine
Wrangle, J., Wang, W., Koch, A., Easwaran, H., Mohammad, H. P., Pan, X., Vendetti, F., VanCriekinge, W., DeMeyer, T., Du, Z., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1542 · Cited by 386
Self-citationBender, C. M., Pao, M. M., & Jones, P. A. (1998) · PubMed · Cited by 380
Self-citationPolo, S. E., Kaidi, A., Baskcomb, L., Galanty, Y., & Jackson, S. P. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.188 · Cited by 374
Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia
Ntziachristos, P., Tsirigos, A., Welstead, G. G., Trimarchi, T., Bakogianni, S., Xu, L., Loizou, E., Holmfeldt, L., Strikoudis, A., King, B., et al. (2014) · Nature · doi:10.1038/nature13605 · Cited by 365
Epigenetic Therapeutics: A New Weapon in the War Against Cancer
Ahuja, N., Sharma, A. R., & Baylin, S. B. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-111314-035900 · Cited by 363
Self-citationDNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes
Shen, L., Kantarjian, H., Guo, Y., Lin, E., Shan, J., Huang, X., Berry, D., Ahmed, S., Zhu, W., Pierce, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4781 · Cited by 355
Self-citationThe future of epigenetic therapy in solid tumours—lessons from the past
Azad, N., Zahnow, C. A., Rudin, C. M., & Baylin, S. B. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.42 · Cited by 335
Self-citationCombining Epigenetic and Immunotherapy to Combat Cancer
Chiappinelli, K. B., Zahnow, C. A., Ahuja, N., & Baylin, S. B. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2125 · Cited by 309
Self-citationOakes, C. C., Seifert, M., Assenov, Y., Gu, L., Przekopowitz, M., Ruppert, A. S., Wang, Q., Imbusch, C. D., Serva, A., Koser, S. D., et al. (2016) · Nature Genetics · doi:10.1038/ng.3488 · Cited by 307
Weber, J. S., Salgaller, M. L., Samid, D., Johnson, B., Herlyn, M., Lassam, N. J., Treisman, J. S., & Rosenberg, S. A. (1994) · PubMed · Cited by 294
McGarvey, K. M., Fahrner, J. A., Greene, E., Martens, J., Jenuwein, T., & Baylin, S. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2481 · Cited by 286
Self-citationIssa, J.-P. J., Roboz, G., Rizzieri, D., Jabbour, E., Stock, W., O'Connell, C., Yee, K., Tibes, R., Griffiths, E. A., Walsh, K., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00038-8 · Cited by 283
Self-citationFandy, T. E., Herman, J. G., Kerns, P., Jiemjit, A., Sugar, E. A., Choi, S.-H., Yang, A. S., Aucott, T., Dauses, T., Odchimar-Reissig, R., et al. (2009) · Blood · doi:10.1182/blood-2009-02-203547 · Cited by 282
DNA methylation models histone acetylation
Eden, S., Hashimshony, T., Keshet, I., Cedar, H., & Thorne, A. W. (1998) · Nature · doi:10.1038/29680 · Cited by 276
Traina, F., Visconte, V, Elson, P., Tabarroki, A., Jankowska, A. M., Hasrouni, E., Sugimoto, Y., Szpurka, H., Makishima, H., O'Keefe, C. L., et al. (2014) · Leukemia · doi:10.1038/leu.2013.269 · Cited by 269
DNA Methylation Changes after 5-Aza-2′-Deoxycytidine Therapy in Patients with Leukemia
Yang, A. S., Doshi, K. D., Choi, S.-W., Mason, J. B., Mannari, R. K., Gharybian, V., Luna, R., Rashid, A., Shen, L., Estecio, M. R. H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2385 · Cited by 266
Self-citationReactivating the expression of methylation silenced genes in human cancer
Karpf, A. R., & Jones, D. A. (2002) · Oncogene · doi:10.1038/sj.onc.1205602 · Cited by 264
Mutant BRAF Melanomas—Dependence and Resistance
Poulikakos, P. I., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.008 · Cited by 250
Prebet, T., Sun, Z., Figueroa, M. E., Ketterling, R., Melnick, A., Greenberg, P. L., Herman, J., Juckett, M., Wang, E. S., Smith, M. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.3102 · Cited by 246
The NuRD chromatin–remodeling complex regulates signaling and repair of DNA damage
Smeenk, G., Wiegant, W. W., Vrolijk, H., Solari, A. P., Pastink, A., & van Attikum, H. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201001048 · Cited by 243
Turcan, S., Fabius, A. W. M., Borodovsky, A., Pedraza, A., Brennan, C., Huse, J., Viale, A., Riggins, G. J., & Chan, T. A. (2013) · Oncotarget · doi:10.18632/oncotarget.1412 · Cited by 240
DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors.
Zhu, W., Lakshmanan, R. R., Beal, M. D., & Otterson, G. A. (2001) · PubMed · Cited by 226
Zhu, W.-G., & Otterson, G. (2003) · Current Medicinal Chemistry-Anti-Cancer Agents · doi:10.2174/1568011033482440 · Cited by 226
Bhadury, J., Nilsson, L. M., Veppil Muralidharan, S., Green, L. C., Li, Z., Gesner, E. M., Hansen, H. C., Keller, U. B., McLure, K. G., & Nilsson, J. A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406722111 · Cited by 212
Role of Nucleosomal Occupancy in the Epigenetic Silencing of the MLH1 CpG Island
Lin, J. C., Jeong, S., Liang, G., Takai, D., Fatemi, M., Tsai, Y. C., Egger, G., Gal-Yam, E. N., & Jones, P. A. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.10.014 · Cited by 206
Self-citationKarpf, A. R., Peterson, P. W., Rawlins, J. T., Dalley, B. K., Yang, Q., Albertsen, H., & Jones, D. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.14007 · Cited by 196
Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents
Héninger, E., Krueger, T. E. G., & Lang, J. M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00029 · Cited by 194
Fiskus, W., Sharma, S., Qi, J., Valenta, J. A., Schaub, L. J., Shah, B., Peth, K., Portier, B. P., Rodriguez, M., Devaraj, S. G. T., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0770 · Cited by 190
SWI/SNF chromatin remodeling complexes and cancer
Biegel, J. A., Busse, T. M., & Weissman, B. E. (2014) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.31410 · Cited by 183
Fang, F., Balch, C., Schilder, J., Breen, T., Zhang, S., Shen, C., Li, L., Kulesavage, C., Snyder, A. J., Nephew, K. P., et al. (2010) · Cancer · doi:10.1002/cncr.25204 · Cited by 176
G9a, a multipotent regulator of gene expression
Shankar, S. R., Bahirvani, A. G., Rao, V. K., Bharathy, N., Ow, J. R., & Taneja, R. (2013) · Epigenetics · doi:10.4161/epi.23331 · Cited by 169
Long-term haematopoietic reconstitution by Trp53-/-p16Ink4a-/-p19Arf-/- multipotent progenitors
Akala, O. O., Park, I.-K., Qian, D., Pihalja, M., Becker, M. W., & Clarke, M. F. (2008) · Nature · doi:10.1038/nature06869 · Cited by 169
ICGC MMML-Seq project, Kretzmer, H., BLUEPRINT project, Bernhart, S. H., Wang, W., Haake, A., Weniger, M. A., Bergmann, A. K., Betts, M. J., Pau, E. C. D. S., et al. (2015) · Nature Genetics · doi:10.1038/ng.3413 · Cited by 156
Histone deacetylase inhibitors as anti-neoplastic agents
Batty, N., Malouf, G. G., & Issa, J. J. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.03.013 · Cited by 156
Self-citationPhenotypic conversion of cultured mouse embryo cells by aza pyrimidine nucleosides
Constantinides, P. G., Taylor, S. M., & Jones, P. A. (1978) · Developmental Biology · doi:10.1016/0012-1606(78)90273-7 · Cited by 150
Self-citationMechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome
Qin, T., Castoro, R. J., Ahdab, S. E., Jelı́nek, J., Wang, X., Si, J., Shu, J., He, R. L., Zhang, N., Chung, W., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023372 · Cited by 139
Self-citationStewart, D. J., Issa, J. J., Kurzrock, R., Nunez, M. I., Jelı́nek, J., Hong, D. S., Oki, Y., Guo, Z., Gupta, S. K., & Wistuba, I. I. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2196 · Cited by 139
Self-citationEffect of Cytarabine and Decitabine in Combination in Human Leukemic Cell Lines
Qin, T., Youssef, E. M., Jelínek, J., Chen, R., Yang, A. S., Garcia‐Manero, G., & Issa, J. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2762 · Cited by 137
Self-citationCai, Y., Geutjes, E.-J., de Lint, K., Roepman, P., Bruurs, L. J. M., Yu, L., Wang, W., van Blijswijk, J., Mohammad, H. P., de Rink, I., et al. (2013) · Oncogene · doi:10.1038/onc.2013.178 · Cited by 135
Self-citationRaynal, N. J. ‐., Si, J., Taby, R. F., Gharibyan, V., Ahmed, S., Jelı́nek, J., Estecio, M. R., & Issa, J. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3248 · Cited by 135
Self-citationTargeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer
Raynal, N. J. ‐., Lee, J. T., Wang, Y., Beaudry, A., Madireddi, P., Garriga, J., Malouf, G. G., Dumont, S., Dettman, E. J., Gharibyan, V., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-2391 · Cited by 110
Self-citationEpigenetic therapies for chemoresensitization of epithelial ovarian cancer
Matei, D. E., & Nephew, K. P. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.09.043 · Cited by 106
Karpf, A. R. (2006) · Epigenetics · doi:10.4161/epi.1.3.2988 · Cited by 99
Prébet, T., Sun, Z., Ketterling, R. P., Zeidan, A. M., Greenberg, P. L., Herman, J. G., Juckett, M., Smith, M. R., Malick, L., Paietta, E. M., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13832 · Cited by 99
The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer
Fang, F., Munck, J. M., Tang, J., Taverna, P., Wang, Y., Miller, D. F., Pilrose, J. M., Choy, G. S., Azab, M., Pawelczak, K. S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1553 · Cited by 97
Jin, L., Hanigan, C. L., Wu, Y., Wang, W., Park, B. H., Woster, P. M., & Casero, R. A. (2012) · Biochemical Journal · doi:10.1042/bj20121360 · Cited by 93
Yamazaki, J., Jelinek, J., Lu, Y., Cesaroni, M., Madzo, J., Neumann, F., He, R., Taby, R., Vasanthakumar, A., Macrae, T., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-0739 · Cited by 89
Self-citationon behalf of the EORTC Leukemia Group and the German MDS Study Group, Lübbert, M., Suciu, S., Hagemeijer, A., Rüter, B. H., Platzbecker, U., Giagounidis, A. A. N., Selleslag, D., Labar, B., Germing, U., et al. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2547-0 · Cited by 88
Łuszczek, W., Cheriyath, V., Mekhail, T. M., & Borden, E. C. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0309 · Cited by 87
Oki, Y., Jelı́nek, J., Shen, L., Kantarjian, H. M., & Issa, J. J. (2007) · Blood · doi:10.1182/blood-2007-07-103960 · Cited by 74
Self-citationEnvironmental exposures and mutational patterns of cancer genomes
Pfeifer, G. P. (2010) · Genome Medicine · doi:10.1186/gm175 · Cited by 74
Chai, G., Li, L., Zhou, W., Wu, L., Zhao, Y., Wang, D., Lu, S., Yu, Y., Wang, H., McNutt, M. A., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002445 · Cited by 72
The current status of targeted therapy for non‐small cell lung cancer
Francis, H., & Solomon, B. (2009) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2009.02141.x · Cited by 66
Aparicio, A. M., North, B., Barske, L. A., Wang, X., Bollati, V., Weisenberger, D. J., Yoo, C. B., Tannir, N. M., Horne, E., Groshen, S. G., et al. (2009) · Epigenetics · doi:10.4161/epi.4.3.8694 · Cited by 58
Self-citationBenson, E. A., Skaar, T. C., Liu, Y., Nephew, K. P., & Matei, D. E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141279 · Cited by 57
Epigenetic Modulators and the New Immunotherapies
Dear, A. E. (2016) · New England Journal of Medicine · doi:10.1056/nejmcibr1514673 · Cited by 57
IDH2 inhibition in AML: Finally progress?
Stein, E. M. (2015) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2015.10.016 · Cited by 52
Current status of targeted therapy in non small cell lung cancer (NSCLC)
Parums, D. (2014) · Drugs of today · doi:10.1358/dot.2014.50.7.2185913 · Cited by 51
Silverman, L. R., Verma, A. K., Odchimar-Reissig, R., LeBlanc, A., Najfeld, V., Gabrilove, J. L., Isola, L. M., Espinoza‐Delgado, I., & Zwiebel, J. A. (2008) · Blood · doi:10.1182/blood.v112.11.3656.3656 · Cited by 50
Decitabine reactivated pathways in platinum resistant ovarian cancer
Fang, F., Zuo, Q., Pilrose, J. M., Wang, Y., Shen, C., Li, M., Wulfridge, P., Matei, D. E., & Nephew, K. P. (2014) · Oncotarget · doi:10.18632/oncotarget.1961 · Cited by 49
Current status of targeted therapy in non small cell lung cancer (NSCLC)
Parums, D. V. (2014) · Drugs of today · doi:10.1358/dot.2014.50.07.2185913 · Cited by 40
Beck, S., Bernstein, B., Campbell, R. M., Costello, J., Dhanak, D., Ecker, J. R., Greally, J. M., Issa, J. J., Laird, P. W., Polyák, K., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-3658 · Cited by 27
Self-citationGarcia‐Manero, G., Yang, A. S., Klimek, V. M., Cortes, J. E., Ravandi, F., Newsome, W. M., Dumouchel, J., Dubay, M., Li, Z., Maroun, C. R., et al. (2007) · Blood · doi:10.1182/blood.v110.11.444.444 · Cited by 26
Cited by
Hallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887
The role of m6A modification in the biological functions and diseases
Jiang, X., Liu, B., Nie, Z., Duan, L., Xiong, Q., Jin, Z., Yang, C., & Chen, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00450-x · Cited by 2,335
The DNA methyltransferase family: a versatile toolkit for epigenetic regulation
Lyko, F. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2017.80 · Cited by 1,467
Epigenetic plasticity and the hallmarks of cancer
Flavahan, W. A., Gaskell, E., & Bernstein, B. E. (2017) · Science · doi:10.1126/science.aal2380 · Cited by 1,340
Circular RNAs in cancer: opportunities and challenges in the field
Kristensen, L. S., Hansen, T. B., Venø, M. T., & Kjems, J. (2018) · Oncogene · doi:10.1038/onc.2017.361 · Cited by 1,326
Metadata
- Authors
- Jones, P. A., Issa, J.-P. J., & Baylin, S.
- Venue
- Nature Reviews Genetics
- Published
- 2016-09-15
- Volume
- 17
- Issue
- 10
- Pages
- 630-641
- ISSN
- 1471-0056 (ISSN-L)
- 1471-0064
- OpenAlex
- W2519953954
- Cited by
- 1,128
- References
- 141
- FWCI
- 9.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.